Investigation of factors which are related to urinary volume change after canagliflozin administratio
- Conditions
- Type2 diabetes mellitus
- Registration Number
- JPRN-UMIN000019462
- Lead Sponsor
- Medical Corporation Hokubukai Utsukushigaoka Hospital, Clinical Pharmacology Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Not provided
1. Patients who have not received treatment of type 2 diabetes mellitus(diet therapy, exercise therapy, oral hypoglycemic agent and so on) 2. Patient with type 1 diabetes mellitus or with history of secondary diabetes mellitus 3. Patients who have experienced repeated severe hypoglycemic episodes 4. Patients with the history of serious diabetic complications requiring treatment 5. Patients treated with insulin, GLP-1 receptor agonist, SGLT-2 inhibitor, diuretic (including drug combination) 6. Patients with history of , or concurrent complication that affect renal function(renal disease, renal stone, prostatic inflammation and so on) , or patients with urinary-tract infection 7. Patients with history of drug or food allergies 8. Patients with history of myocardial infarction, congestive heart failure, unstable angina, cerebrovascular disease(except for lacunar infarction)within 6 months prior to screening visit (confirmation of eligibility) 9. Patients with history of TIA or cerebral infarction with clear neurological symptoms 10. Patients with peripheral arterial disease; Fontaine grade 3 or 4 11. Patients who correspond to contraindication or careful administration of canagliflozin (except for patient under treatment of hypoglycemic agents) 12. Patients with history of atrial fibrillation 13. Patients who are judged as inappropriate by investigators on screening examination.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method